Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider John Patrick Shannon, Jr. acquired 30,769 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were bought at an average cost of $1.64 per share, for a total transaction of $50,461.16. Following the transaction, the insider now directly owns 1,408,575 shares in the company, valued at $2,310,063. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Xeris Biopharma Price Performance
Shares of NASDAQ XERS opened at $1.77 on Monday. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $3.07. The stock has a market cap of $244.48 million, a price-to-earnings ratio of -3.93 and a beta of 2.03. The company has a debt-to-equity ratio of 49.27, a quick ratio of 1.38 and a current ratio of 1.82. The firm’s 50-day simple moving average is $1.79 and its 200 day simple moving average is $2.29.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on XERS shares. HC Wainwright cut their price objective on shares of Xeris Biopharma from $6.00 to $5.50 and set a “buy” rating on the stock in a research report on Monday, November 13th. Craig Hallum started coverage on shares of Xeris Biopharma in a research report on Monday, August 28th. They set a “buy” rating and a $4.50 price objective on the stock. Finally, Piper Sandler cut their price objective on shares of Xeris Biopharma from $5.00 to $4.00 and set an “overweight” rating on the stock in a research report on Friday, November 10th.
Hedge Funds Weigh In On Xeris Biopharma
Several large investors have recently added to or reduced their stakes in XERS. Cetera Advisor Networks LLC lifted its position in Xeris Biopharma by 7.4% in the 1st quarter. Cetera Advisor Networks LLC now owns 91,656 shares of the company’s stock valued at $235,000 after acquiring an additional 6,281 shares in the last quarter. Citigroup Inc. increased its stake in Xeris Biopharma by 8,907.0% in the 1st quarter. Citigroup Inc. now owns 335,150 shares of the company’s stock valued at $858,000 after buying an additional 331,429 shares during the last quarter. BlackRock Inc. increased its stake in Xeris Biopharma by 11.1% in the 1st quarter. BlackRock Inc. now owns 1,994,879 shares of the company’s stock valued at $5,107,000 after buying an additional 199,366 shares during the last quarter. Vanguard Group Inc. increased its stake in Xeris Biopharma by 1.8% in the 1st quarter. Vanguard Group Inc. now owns 5,208,186 shares of the company’s stock valued at $13,333,000 after buying an additional 92,563 shares during the last quarter. Finally, Ergoteles LLC purchased a new stake in Xeris Biopharma in the 1st quarter valued at about $65,000. Institutional investors own 40.51% of the company’s stock.
Xeris Biopharma Company Profile
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
- Five stocks we like better than Xeris Biopharma
- How to Invest in the Entertainment Industry
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- The “How” and “Why” of Investing in 5G Stocks
- MarketBeat Week in Review – 11/13 – 11/17
- Insider Trades May Not Tell You What You Think
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.